Editas Medicine, Inc.
EDIT
Jodie situation report
Editas Medicine, Inc.'s move is being confirmed by its market group.
No new filing conclusion is available. 28 of 31 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 8 directly disclosed connections are confirming.
- At least 21 of 31 members remain active in the next snapshot.
- Capital-flow agreement rises above 55%.
- A filing-linked outsider such as NRIX begins moving with the group.
Invalidation: The live read weakens if participation falls to 10 of 31 members or fewer.
Who this business touches
The relationships behind EDIT
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
BMYBristol-Myers Squibb CompanypartnerMar 9, 2026 ▾
“For example, our collaboration with Bristol Myers Squibb Company (“BMS”) through its wholly owned subsidiary, Juno Therapeutics, Inc.”
IMTXImmatics N.V.partnerMar 9, 2026 ▾
“We are also party to a non-exclusive collaboration and licensing agreement with Immatics to combine gamma-delta T cell adoptive cell therapies and gene editing for the treatment of cancer.”
Depended on by
VRTXVertex Pharmaceuticals IncorporatedpartnerFeb 13, 2026 ▾
“In December 2023, we entered into an agreement with Editas Medicine, Inc.”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 5 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
EDIT is currently a Participant in the organic co-movement group Biotechnology Therapeutics. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.